Eplerenone is a selective mineralocorticoid receptor antagonist. Its approved for the therapy of patients with chronic heart failure with left ventricular systolic dysfunction and for the patients after myocardial infarction complicated by heart failure and left ventricular dysfunction. It´s also recommended for the therapy of primary hyperaldosteronism and the treatment of drug resistant hypertension.
Keyphrases
- left ventricular
- heart failure
- drug resistant
- ejection fraction
- cardiac resynchronization therapy
- aortic stenosis
- multidrug resistant
- blood pressure
- end stage renal disease
- acinetobacter baumannii
- cardiovascular disease
- hypertrophic cardiomyopathy
- acute myocardial infarction
- oxidative stress
- newly diagnosed
- mitral valve
- left atrial
- prognostic factors
- coronary artery disease
- peritoneal dialysis
- type diabetes
- atrial fibrillation
- patient reported outcomes
- combination therapy
- mesenchymal stem cells
- stem cells
- cardiovascular events
- cystic fibrosis